We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Signaling Protein Stabilizes Heterochromatin and Suppresses Tumor Growth

By LabMedica International staff writers
Posted on 20 Jun 2013
Genomics researchers have found that the unphosphorylated form of the STAT5A signaling protein functions as a tumor suppressor by stabilizing heterochromatin, which blocks the expression of multiple oncogenes.

STAT5A (signal transducer and activator of transcription 5A) is a member of the STAT protein family, which regulates many aspects of cell growth, survival, and differentiation. More...
Disruption of this signaling pathway is frequently observed in primary tumors and leads to increased angiogenesis and enhanced tumor survival. Knockout studies have provided evidence that STAT proteins are involved in the development and function of the immune system, and play a role in maintaining immune tolerance and tumor surveillance. STAT5A is activated by and it mediates the responses of many cell ligands, such as interleukins and growth hormones.

Investigators at the University of California, San Diego School of Medicine (USA; www.ucsd.edu) and their colleagues at the University of Rochester Medical Center (NY, USA) worked with a mouse xenograft colon cancer model to study the effects of STAT5A.

They reported in the June 3, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that unphosphorylated STAT5A bound to the heterochromatin protein 1-alpha (HP1-alpha) and stabilized the heterochromatin. Expressing unphosphorylated STAT5A or HP1-alpha inhibited colon cancer growth in the mouse xenograft model.

Previous experiments conducted in fruit flies had shown that the unphosphorylated form of STAT5A caused chromatin to condense into heterochromatin, while the phosphorylated form prompted dispersal and loss of heterochromatin, furthering gene expression.

“Unphosphorylated STAT promotes and stabilizes heterochromatin formation, which in turn suppresses gene transcription,” said senior author Dr. Willis X. Li, professor of medicine at the University of California, San Diego School of Medicine. “When we expressed either HP1-alpha (the central component of heterochromatin) or unphosphorylated STAT5A in human cancer cells, many genes important for cancer growth are suppressed. These cancer cells do not grow as fast or big as their control parental cancer cells in mouse xenograft models.”

Transcriptome profiling showed that expressing unphosphorylatable STAT5A had similar effects to overexpressing HP1-alpha in global gene expression. The majority of the genes commonly repressed by unphosphorylated STAT5A and HP1-alpha have been implicated in cancer development, and down regulation, somatic mutations, and deletions of STAT5 genes are found in certain human cancers.

“We are in the process of identifying small molecule drugs that may promote heterochromatin formation without stopping cell division or causing cell death,” said Dr. Li. “These drugs, if found, may be effective in treating cancers with fewer side effects.”

Related Links:
University of California, San Diego School of Medicine
University of Rochester Medical Center



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
HPV Test
Allplex HPV28 Detection
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.